Gilead’s Profit, Hepatitis C Drugs Sales Miss Estimates

  • Sovaldi, Harvoni sales disappoint after competitors appear
  • Company is `aggressively' seeking investment opportunities

Gilead Sciences Inc.’s profit missed analysts’ estimates in the first quarter as sales of its blockbuster hepatitis C treatments were lower than expected.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.